Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives

K Papamichael, W Afif, D Drobne… - The lancet …, 2022 - thelancet.com
Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimising the use of
biologics, and in particular anti-tumour necrosis factor (anti-TNF) therapy, in inflammatory …

Artificial intelligence and machine learning approaches to facilitate therapeutic drug management and model-informed precision dosing

EA Poweleit, AA Vinks, T Mizuno - Therapeutic drug monitoring, 2023 - journals.lww.com
Background: Therapeutic drug monitoring (TDM) and model-informed precision dosing
(MIPD) have greatly benefitted from computational and mathematical advances over the …

Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn's disease

RJ Colman, Y **ong, T Mizuno… - Alimentary …, 2022 - Wiley Online Library
Background Antibodies to infliximab (ATI) are associated with secondary loss of response
and increased risk for drug reactions. Limited studies have associated ATI with increased …

Precision dosing of anti-TNF therapy in pediatric inflammatory bowel disease

A Samuels, KG Whaley, P Minar - Current gastroenterology reports, 2023 - Springer
Abstract Purpose of the Review This review focuses on recent advancements in anti-TNF
therapeutic drug monitoring (TDM), pharmacogenetics and personalized drug selection for …

Failure to achieve target drug concentrations during induction and not HLA-DQA1∗ 05 carriage is associated with antidrug antibody formation in patients with …

EA Spencer, J Stachelski, T Dervieux… - …, 2022 - gastrojournal.org
In 2020 the PANTS (Personalising Anti-TNF Therapy in Crohn's Disease) study reported an
association between HLADQA1* 05 and the development of antidrug antibodies (ADAs) to …

A model-based tool for guiding infliximab induction dosing to maximize long-term deep remission in children with inflammatory bowel diseases

W Kantasiripitak, SG Wicha, D Thomas… - Journal of Crohn's …, 2023 - academic.oup.com
Abstract Background and Aims Adequate infliximab concentrations during induction
treatment are predictive for deep remission [corticosteroid-free clinical and endoscopic …

Multicenter cohort study of infliximab pharmacokinetics and therapy response in pediatric acute severe ulcerative colitis

KG Whaley, Y **ong, R Karns, JS Hyams… - Clinical …, 2023 - Elsevier
Background & aims We aimed to model infliximab (IFX) pharmacokinetics (PK) in pediatric
acute severe ulcerative colitis (ASUC) and assess the association between PK parameters …

Eculizumab precision-dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT

K Mizuno, CE Dandoy, A Teusink-Cross… - Blood …, 2022 - ashpublications.org
Transplant-associated thrombotic microangiopathy (TA-TMA) is a fatal posttransplant
complication of hematopoietic stem cell transplantation. We recently reported that survival …

Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of …

RJ Colman, T Mizuno, K Fukushima… - Alimentary …, 2023 - Wiley Online Library
Background Vedolizumab for inflammatory bowel disease (IBD) is often intensified based on
distinct pharmacokinetics in children. Prior adult‐specific population pharmacokinetic …

Tutorial on model selection and validation of model input into precision dosing software for model‐informed precision dosing

ZL Taylor, EA Poweleit, K Paice… - CPT …, 2023 - Wiley Online Library
There has been rising interest in using model‐informed precision dosing to provide
personalized medicine to patients at the bedside. This methodology utilizes population …